Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals

Abstract

Interleukin-6 (IL-6) is a cytokine that regulates the proliferation of some tumor cells including multiple myeloma (MM). Ectopic expression of fibroblast growth factor receptor 3 (FGFR3) associated with the chromosomal translocation, t(4;14)(p16.3;q32), is frequently found in MM, and therefore, has been implicated in the neoplastic transformation of this disease. Here, we show that IL-6 together with FGF enhanced proliferation of a myeloma cell line, KMS-11 carrying t(4;14)(p16.3;q32) and the FGFR3-transfected U266 myeloma cell line which ectopically expressed FGFR3 but responded to neither IL-6 nor FGF alone. In KMS-11, IL-6 activated signal transducer and activator of transcription 3 (STAT3) while FGF activated extracellular signal-regulated kinase 1/2 (ERK1/2) and phosphatidylinositol (PI)-3 kinase. As both MEK inhibitors and a PI 3-kinase inhibitor abolished the effect of IL-6 and FGF, the activation of both the ERK1/2 and PI 3-kinase signaling cascades is essential for the proliferation of KMS-11 enhanced by IL-6 and FGF. Furthermore, the FGF-induced activation of ERK1/2 contributed to the serine phosphorylation of STAT3, suggesting that the signaling crosstalk between the cytokine receptor, IL-6 receptor α/gp130 and the growth factor receptor tyrosine kinase, FGFR3. These results indicate that FGFR3 plays a crucial role in the accelerated proliferation of MM carrying t(4;14)(p16.3;q32).

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 3
Figure 2

Similar content being viewed by others

References

  • Abroun S, Ishikawa H, Tsuyama N, Liu S, Li FJ, Otsuyama K, Zheng X, Obata M and Kawano MM . (2004). Blood, 103, 2291–2298.

  • Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, Rapp MJ, Talmant P, Trimoreau F, Jaccard A, Harousseau JL and Bataille R . (1998). Cancer Res., 58, 5640–5645.

  • Bergsagel PL and Kuehl WM . (2001). Oncogene, 20, 5611–5622.

  • Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schrock E, Reid T and Kuehl WM . (1998a). Blood, 91, 4457–4463.

  • Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM and Bergsagel PL . (2001). Blood, 97, 729–736.

  • Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM and Bergsagel PL . (1997). Nat. Genet., 16, 260–264.

  • Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM and Bergsagel PL . (1998b). Blood, 92, 3025–3034.

  • Chung J, Uchida E, Grammer TC and Blenis J . (1997). Mol. Cell. Biol., 17, 6508–6516.

  • Duarte RF and Frank DA . (2000). Blood, 96, 3422–3430.

  • Fujii R, Ishikawa H, Mahmoud MS, Asaoku H and Kawano MM . (1999). Br. J. Haematol., 105, 131–140.

  • Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, Nakajima K and Hirano T . (1996). Immunity, 5, 449–460.

  • Hirano T, Ishihara K and Hibi M . (2000). Oncogene, 19, 2548–2556.

  • Hirano T, Nakajima K and Hibi M . (1997). Cytokine Growth Factor Rev., 8, 241–252.

  • Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, Chaganti RS and Dalla-Favera R . (1997). Nat. Genet., 17, 226–230.

  • Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Taniguchi O and Kawano MM . (2002). Blood, 99, 2172–2178.

  • Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A and Kishimoto T . (1988). Nature, 322, 83–85.

  • Keegan K, Johnson DE, Williams LT and Hayman MJ . (1991). Proc. Natl. Acad. Sci. USA, 88, 1095–1099.

  • Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M and Hirano T . (1999). J. Exp. Med., 189, 63–73.

  • Klint P and Claesson-Welsh L . (1999). Front. Biosci., 4, 165–177.

  • Mahmoud MS, Ishikawa H, Fujii R and Kawano MM . (1998). Blood, 92, 3887–3897.

  • Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, Lotti V, Compasso S, Bogni S, Lombardi L, Maiolo AT and Neri A . (2000). Cancer Res., 60, 4058–4061.

  • Namba M, Ohtsuki T, Mori M, Togawa A, Wada H, Sugihara T, Yawata Y and Kimoto T . (1989). In vitro Cell. Dev. Biol., 25, 723–729.

  • Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, Miyajima A and Kitamura T . (1998). Mol. Cell. Biol., 18, 3871–3879.

  • Otsuki T, Nakazawa N, Taniwaki M, Yamada O, Sakaguchi H, Wada H, Yawata Y and Ueki A . (1998). Int. J. Oncol., 12, 545–552.

  • Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG and Stewart AK . (2000). Blood, 95, 992–998.

  • Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT and Neri A . (1997). Blood, 90, 4062–4070.

  • Wen Z, Zhong Z and Darnell Jr JE . (1995). Cell, 82, 241–250.

  • Zhang X, Blenis J, Li HC, Schindler C and Chen-Kiang S . (1995). Science, 267, 1990–1994.

Download references

Acknowledgements

KMS-11 and KMS-18 were kindly provided by Proferssor Takemi Otsuki (Kawasaki Medical School, Kurashiki, Japan). We thank Dr Harumi Suzuki (Yamaguchi University) and Prof. Toshio Hirano (Osaka University, Osaka, Japan) for generous gift of pRep and 4xAPRE SpLuc, respectively. We also thank the Center for Gene Research, Yamaguchi University for DNA sequencing. This work was supported in part by grants from the Ministry of Education, Science, Sports and Culture of Japan, the Ministry of Health, Labor and Welfare of Japan, the Japan Society for the Promotion of Science (JSPS), the Yamanouchi Foundation for Research on Metabolic Disorders, Public Trust Haraguchi Memorial Cancer Research Fund and International Myeloma Foundation. JSPS Postdoctoral Fellowship for Foreign Researchers (P04500) awarded to SA.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hideaki Ishikawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ishikawa, H., Tsuyama, N., Liu, S. et al. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene 24, 6328–6332 (2005). https://doi.org/10.1038/sj.onc.1208782

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208782

Keywords

This article is cited by

Search

Quick links